

CLAIMS

1. A drug delivery composition for nasal administration comprising ICAM-1 and a bioadhesive material.  
5
2. A drug delivery composition according to claim 1 wherein the bioadhesive material is a chitosan solution.
3. A drug delivery composition according to claim 2 wherein the chitosan is in the solution in a concentration in the range of 0.2 - 2.0%  
10 w/v.
4. A drug delivery composition according to claim 2 or 3 wherein the ICAM-1 is present in the chitosan solution in a concentration in the range  
15 0.2 to 5% w/v.
5. A drug delivery composition according to claim 1 wherein the bioadhesive material is a plurality of microspheres.  
20
6. A drug delivery composition according to claim 5 wherein the microspheres are made from starch, chitosan, gelatin, hyaluronic acid, alginate or gellan.  
25
7. A drug delivery composition according to claim 5 or 6 wherein the ICAM-1 is present in an amount of 1% to 20% w/w of the microspheres.
8. A drug delivery composition according to claim 1 wherein the bioadhesive material is a liquid formulation comprising a polymeric material.  
30

PCT/GB95/01735

9. A drug delivery composition according to claim 8 wherein the polymeric material is gellan gum, alginate, welan, xanthan or rhamsan.

10. A drug delivery composition according to claim 8 or 9 wherein the  
5 polymeric material is provided in a concentration of 0.1% to 5% w/v.

11. A drug delivery composition according to any one of claims 8 to  
10 wherein the ICAM-1 is present in the formulation in an amount of  
0.2% to 5% w/v.

10

12. A method of delivering ICAM-1 to the nasal cavity to increase its effectiveness therein comprising administering the ICAM-1 in a drug delivery composition additionally comprising a bioadhesive material.

DISCLOSURE DOCUMENT